Teva Pharmaceuticals announced the launch of Capecitabine Tablets, the generic equivalent to Genentech’s Xeloda. Teva is the first company to receive approval for its ANDA for Capecitabine Tablets.

Xeloda is a fluoropyrimidine indicated for metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel when further anthracycline therapy is not indicated; and with docetaxel for metastatic breast cancer after failure of prior anthracycline-containing regimen.

RELATED: Oncology Resource Center

Capecitabine is available in 150mg and 500mg strength tablets.

For more information call (888) 838-2872 or visit